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Abstract
In West and Central Africa, there is a need to establish the prevalence of Wuchereria bancrofti in areas that are co-
endemic for Loa loa, in order to implement the appropriate strategies to scale-up interventions for the elimination of
lymphatic filariasis (LF). Due to the risk of severe adverse events (SAEs) to ivermectin in individuals with high L. loa
microfilaraemia, the current strategy recommended by the World Health Organization (WHO) is twice yearly mass drug
administration (MDA) with albendazole, supplemented by vector control targeting the Anopheles vectors. Defining W.
bancrofti prevalence in areas co-endemic with L. loa is complicated by the cross-reactivity of rapid diagnostic
immunochromatographic card tests (ICT), widely used for LF mapping, in individuals with high L. loa microfilaraemia.
This has probably resulted in the overestimation of LF prevalence, triggering the implementation of MDA strategies,
which may be unnecessary and wasteful of the limited resources for elimination programme implementation. Here we
review the literature and present historical evidence, which uniformly highlight low or no prevalence of W. bancrofti
infection and/or clinical LF cases across five Central African countries, in more than 30 different geographical areas
covering 280 individual sites and > 22,000 individuals tested within high risk L. loa areas. This highlights the very limited
information available on LF prevalence in L. loa areas, and potentially has major policy implications, which could shift the
focus towards revised mapping criteria to verify low or no W. bancrofti prevalence in high risk L. loa areas. In this
situation, revising the current WHO strategy from MDA, to focus more on ensuring high and effective vector control,
through insecticide treated/long-lasting impregnated bednets (ITNs/LLINs), integration of point-of-care test-and-treat
options into health systems, and consolidating closer links with the malaria control programme may be a more effective
and appropriate use of the limited resources and drug donations available for LF elimination.
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Background
Lymphatic filariasis (LF) is a disabling parasitic disease
transmitted by mosquitoes [1]. It is targeted for elimin-
ation and is one of the five neglected tropical diseases
(NTDs) that are primarily controlled by preventive
chemotherapy. The Global Programme to Eliminate LF
(GPELF) has worked towards elimination for nearly two
decades; first by interrupting transmission with mass
drug administration (MDA) using different regimen
combinations of albendazole, ivermectin and diethylcar-
bamazine (DEC), and second by alleviating suffering
through morbidity management and disability preven-
tion (MMDP) [2, 3]. Overall significant progress has
been made towards elimination, but greater efforts are
required in many countries in the World Health Organ-
isation (WHO) African Region, where many countries
remain behind the elimination targets [4].
In 2016, the African region was estimated to have
371.2 million people requiring MDA across 32 endemic
countries, with a reported coverage of 56.9% [3]. While
this marks an increase in coverage from previous years,* Correspondence: Louise.Kelly-Hope@lstmed.ac.uk
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there are still 17 African countries yet to start or
scale-up MDA to full nationwide geographical coverage.
The reasons for limited coverage are complex [5] and re-
lated to several factors including - but not limited to -
political will, conflict, financial commitment, technical
support, difficult to access populations, stakeholder
interest, poverty, poor infrastructure, limited human
capacity, competing priority diseases, and co-endemicity
with the filarial parasite Loa loa, which causes the dis-
ease known as Tropical eye worm or loiasis.
Loa loa occurs in 10 countries in Central and West
Africa (Fig. 1a) [6] and poses two problems for LF elim-
ination. First, the use of ivermectin presents a risk of se-
vere adverse events (SAEs) to individuals with high L.
loa parasitaemias, i.e. > 30,000 microfilariae (Mf) per
millilitre blood, and can induce encephalopathy, coma
and death [7, 8]; secondly by complicating the mapping
of LF distribution as the standard rapid antigen diagnos-
tic tests for LF [e.g. BinaxNOW Filariasis immunochro-
matographic test (ICT) and/or the new Alere Filariasis
Test Strip (FTS Alere, Scarborough, ME, USA)] [9],
cross-react with L. loa, resulting in false positives for
Wuchereria bancrofti, with strong associations between
ICT positivity and L. loa Mfs [10–13], e.g. around 30%
and 50% of ICTs reacting to L. loa when densities were
> 15,00 Mf/ml and > 30,000 Mf/ml respectively [13].
The WHO recommends an alternative strategy for LF
elimination in L. loa co-endemic areas, including twice
yearly MDA with albendazole supplemented with vector
control, primarily insecticide-treated/long-lasting bed-
nets (ITNs/LLINs), which control Anopheles mosquitoes
that transmit both LF and malaria [14]. In addition, a
basic five step model for national LF programmes to
work at implementation unit level has been developed to
supplement the WHO guidelines and help initiate treat-
ment plans [15]; however, countries are still struggling
to implement the strategy. This is complicated by the
lack of clarity on the extent of LF prevalence and
evidence that W. bancrofti transmission is absent or low
in countries with high risk of L. loa, such as Cameroon
and Gabon [3, 16, 17]. This raises questions on how to
accurately map LF in high risk L. loa areas and whether
LF MDA in these areas is warranted.
Here we review existing literature on W. bancrofti
prevalence in high risk L. loa areas, to highlight the ex-
tent of W. bancrofti-L. loa co-endemicity. This may fur-
ther help to refine the needs of national programmes,
and current WHO strategies [14, 15].
Geographical area and search strategy
High risk L. loa areas were defined as those with > 40%
loiasis prevalence determined by the Rapid Assessment
Procedure for Loiasis (RAPLOA) [18, 19], which corre-
lates to 20% Mf prevalence and high risk of SAEs (Fig. 1a).
The geographical high risk L. loa areas and the risk
of LF prevalence mapped within these parameters are
highlighted in Fig. 1b.
A literature search and collation of data was con-
ducted using PubMed, JSTOR, SCOPUS and Google
online sources. Search terms, and combinations thereof,
included Wuchereria bancrofti, lymphatic filariasis,
elephantiasis, Loa loa, loiasis, and tropical eye worm.
Further sources of information were found within refer-
ence section of documents. Due to the cross-reactively
problem associated with antigen tests, studies only using
these tests to determine LF endemicity were excluded.
Evidence from the existing literature
In total, 16 documents with information on LF preva-
lence in humans in high risk L. loa areas were found
between 1928 to 2018. The documents ranged from his-
torical review articles with anecdotal reports, conference
abstracts to specific research articles. Most documents
with specific data were from Cameroon, Gabon and
DRC, and are summarised below and in Table 1.
a Loiasis prevalence b Loiasis high risk and LF low risk
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Fig. 1 Maps of loiasis prevalence and study areas with low LF risk. a Loiasis prevalence. b Loiasis high risk and LF low risk
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Angola
In 2014, a micro-mapping clinical survey was conducted
in Bengo Province in the northern region of Angola in-
cluding 2017 individuals from 29 communities. Clinical
cases of LF were confirmed by medical officers. Eight indi-
viduals had limb lymphoedema (0.4%) and 20 men had
hydrocoele (2.6%) [20]. While clinical cases do not neces-
sarily represent recent transmission, nor define endem-
icity, the relatively low numbers are in line with historical
surveys in the same region in the 1960s [21], and highlight
the probable distribution of isolated foci of W. bancrofti in
northern Angola, with endemic zones in Cabinda District
and the northern region of Zaire District.
Democratic Republic of the Congo
In 2011–2013, a seroprevalence survey was conducted in
30 villages in the Oriental Province in eastern DRC in-
cluding 2724 individuals (aged ≥ 14 years) from the Ituri
region (Mambasa Territory) and Haute Uele region
(Watsa Territory) [10]. The presence of W. bancrofti was
assessed by examining night blood slides for Mf by mi-
croscopy and parasite DNA by quantitative real-time
polymerase chain reaction (qPCR). Only one individual
was positive for W. bancrofti DNA.
In 1974, a study in 32 villages in the Mayumbe region
on the western coast of DRC, close to the mouth of the
Congo River, including 2476 adult individuals who had
lived in that region for at least 5 years. Only one village
was positive for W. bancrofti by night blood slide Mf mi-
croscopy [22].
Cameroon
In 2017, two studies from Cameroon highlighted the ab-
sence of W. bancrofti in L. loa endemic areas [16, 17].
Wanji et al. [16] reported a seroprevalence study of 5000
individuals from 50 villages across the South, Central,
South-east, North-west, Far-north areas of the country,
which detected no W. bancrofti positivity using two dif-
ferent antibody Wb123 tests, examining night blood
slides for Mf and confirming selected samples with
pPCR methods. Similarly, Biholong et al. [17] reported
on a seroprevalence study conducted in 2010–2012 of
14,577 individuals (aged ≥ 9 years), across 31 health dis-
tricts which detected no W. bancrofti Mf by night blood
slide in 185 of the 235 individuals who were initially
found to be antigen-positive using FTS.
In 2016, a study examining the geographical distribu-
tion of podoconiosis using parasitological, serological
and clinical evidence to exclude the causes of lymphoe-
dema, including LF was conducted across ten Regions of
Cameroon. In the four high risk L. loa regions, i.e. the
Central, East, Littoral and South Regions, a total of 4698
people from 29 communities were examined. In total 24
lymphoedema cases were found in these four Regions,
and of these one was FTS-positive (Littoral Region) and
none were positive by Mf, Wb123 and qPCR test [23].
Table 1 Summary of studies examining Wuchereria bancrofti human infection
Country Study
yeara





Angola 2015 Bengo Province Clinical 29 2017 [20]
DRC 2013 Oriental Province Mf 30 2724 [10]
1974a Mayombe, Bas Congo Province Mf 32 2476 [22]
Cameroon 2018 East, Central, South, Littoral Clinical; Mf; Wb123;
qPCR
29 4698 (24)c [23]
2017b South, Central, South-east, North West, Far
North
Wb123; qPCR 50 5000 [16]
2016 East, Central, South, Littoral Mf 31 14,577 (185)c [17]
2016 Messok District, Haut-Nyong Department qPCR 8 1085 [24]
2013 Lolodorf surrounds Wb123; qPCR 26 1812 [13]
2013 East, North-west, South-west Mf; Clinical 42 2190 (24)c [11]
1990a Goura, Badissa Nyamanga Mf 3 1324 [25, 29]
1975 Department Mifi Mf; Clinical 6 1004 [25, 28]
1957a Yoko Region Mf 1 50 [25, 27,
36]
Total 287 38,957 (22,399)d
aIndicates publication year, when study year is not stated
bThe exact numbers in the high risk Loa areas is unclear until publication i.e. the North, West, far West have minimal or no overlap with high risk areas, and
therefore related numbers are likely not to count
cIndicates the number of individuals initially examined for clinical conditions or using ICT or FTS (with positive cases examined further using different
diagnostic tests)
dIndicates total number of individuals examined (total number excluding ICT or FTS)
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Additional findings in 2013 and 2016 suggested no LF.
These included a seroprevalence study in eight villages
in Messok District [24], including 1085 individuals (the
majority aged > 15 years) in 2016, and a seroprevalence
study in 26 communities within 50 km of Lolodorf,
southern Cameroon, including 1812 individuals (aged ≥
5 years) in 2013 [13]. The absence of W. bancrofti was
confirmed by qPCR and Wb123 assays in 52 individuals
initially found to be antigen-positive using ICTs. All
other ICTs were negative.
Another seroprevalence study in 42 communities in
the East, North-west and South-west of the Cameroon
rainforest belt, including 2190 individuals (aged > 10
years) in 2013, found no W. bancrofti Mf by night blood
slide in 24 individuals that were antigen-positive using
ICTs. Twenty cases of lymphoedema were found and
none of them were ICT-positive. No cases of hydrocele
were found.
A review by Boussinesq in 1999 [25], of historical
studies published in French, highlighted that in 1928,
Sharp [26] found very low W. bancrofti Mf prevalence
0.4–2.0% in Mamfe region; in 1957, Languillion [27] re-
ported no W. bancrofti Mf in 50 individuals from Yoko
region; in 1975, Brengues [28] reported no W. bancrofti
filaria in six localities in the Department of Mifi includ-
ing 1004 individuals, and 32 cases of elephantiasis
among 2395 individuals clinically examined; in 1990,
Lochouarn [29] found no W. bancrofti Mf in three
villages, Goura (Department du Mbam et Kim), Badissa
and Nyamanga (Mbam et Inoubou) including 1324
individuals (aged > 10 years).
Excerpts from historical and/or anecdotal reports
While rigorous data on LF distribution in L. loa areas is
limited, there are many anecdotal and historical reports
that W. bancrofti across Central Africa is low or absent.
These are presented here as excerpts with the approxi-
mate decade and country of the review, study or publica-
tion to provide perspective on time frame and place.
“W. bancrofti is said not to be found from the Uele
river in the Belgian Congo to the Coast or from the
Ouham river to Gabon. Nor has it been found in
Gabon, according to Galliard. At M’Bomou (a head
tributary of the Ubangui river), W. bancrofti was not
found in 400 night bloods, although elephantiasis
occurs; this is said to be due to Onchocerca.”
(~1910–1950s; Gabon) [30–32]
“… elephantiasis, on the contrary, is rather rare and
a very limited distribution” (~1910s; French Equatorial
Africa) [32]
“In the Cameroons, we have never found the
microfilariae in night surveys in five large villages in the
rainforest, not during the day in many thousands of
bloods films. Elephantiasis only occurs in the rainforest
where infection with O. volvulus is found.”
(1950s; Cameroon) [30]
“It has never been encountered in many thousands of
similar blood films taken in the Cameroons.”
(~1950s; Cameroon) [33]
“In most of Belgian Congo, however, filariasis seems
to be rare and unimportant.”
(~1950s; Belgian Congo) [30]
“… in 1924, an extensive investigation into the
incidence of infection by L. loa and A. perstans, and
found that the percentage of population infection with L.
loa was 17, with A. perstans 77, and with F. bancrofti
only 0.4.” (~1920s; Cameroon) [26, 30]
“In Ayos, W. bancrofti is never seen.”
(~1930s; French Cameroons) [30]
“In the Bankim district, located in the Tikar plain,
the 10 surveyed villages were all hyperendemic for
loiasis. … The low prevalence of hydroceles suggests that
lymphatic filariasis is not endemic in this study area.”
(~2000s; Cameroon) [34]
“According to Languillon (1957) the microfilaria rate
is 16% in the savanna region of the north (Diamare and
Benoue), but falls to 0.8% in the forest zone of the
south…” (1950s; Cameroon) [27, 35]
“Infection with W. bancrofti is considered to be slight
but there is little evidence on the subject (Hamon et al.
1967). Brumpt et al. (1972) who examined 100 persons
in two small villages in the north near the Chad
frontier, detected one case of infection with this parasite.”
(1960s; Central African Republic) [35–37]
“ … In the western region of Nigeria, with special
reference to the Ibadan area, W. bancrofti was very rare
in this region. … On the other hand, Ibadan lies in the
heart of the Loa belt of West Africa and its infection
there is common.” (~1970s; Nigeria) [38]
“For the Gabonese population one can
approximately say that 3 out of 5 adult patients have
filariasis, two being D. perstans and one L. loa.
Consequently, these affections represent a major public
health problem. Finally, one must note that no cases of
lymphatic filariasis has been identified.”
(~ 1980s; Gabon) [39]
“Because only a few infections were identified across
Gabon … undergoing remapping to determine whether
MDA for LF is warranted,” (~2010s; Gabon) [3]
Conclusions
This review highlights the very limited information avail-
able on LF prevalence in L. loa areas. The data that are
available are consistent with anecdotal historical reports
indicating that LF is very low or absent in high risk L.
loa areas. The distinct ecological niches of the filarial
parasites and their various vectors may explain these
Kelly-Hope et al. Parasites & Vectors  (2018) 11:349 Page 4 of 6
differences, i.e. Anopheles species transmitting W. ban-
crofti may prefer savanna-like habitats more than the
deep forested ecology, where the L. loa vector Chrysops
species thrive, and there may be competitive exclusion,
given the co-endemicity of five human filarial parasites
in these countries [40]. Regardless, these findings have
major implications for co-endemic countries, and
GPELF, and may significantly reduce the need for MDA
for millions of people across vast geographical areas of
Central and West Africa as noted recently in Cameroon
[16, 17], with consequent resource implications. It is im-
portant that further confirmatory mapping is conducted,
with appropriate population-based sampling strategies,
including individuals over five years of age. Sentinel site
surveys are not sufficient as the geographical scale is not
sufficiently refined to detect focal transmission hotspots
in low endemic areas. Targeted micro-mapping may be
more suitable [20, 41, 42], especially in areas that are
ecologically diverse where the co-endemicity may vary
and different diagnostic tools may be required. Better
delineation of where the rapid antigen test for W.
bancrofti can or should be used is important (e.g. in low
risk L. loa areas) as they may help to identify regions
that do not require MDA [13]. Equally, it will be import-
ant to identify areas where alternative W. bancrofti diag-
nostics may be more appropriate to use such as the
antibody Wb123-based mono or biplex test, qPCR or
microscopy (e.g. high risk L. loa areas). Further, it will
also be important to distinguish between LF clinical
manifestations and other diseases with similar clinical
presentations, notably podoconiosis (or non-filarial
lymphoedema), which appears to be endemic in some of
these countries [23, 43]. Monitoring the impact of other
interventions used in these areas will be critical. The
widespread distribution of community-directed treat-
ment with ivermectin (CDTI) for onchocerciasis control
may have impacted W. bancrofti transmission as shown
elsewhere [44, 45]. Similarly, the recent significant
scale-up of vector control for malaria, primarily ITNs/
LLINs, which has reduced malaria prevalence [46], may
have reduced W. bancrofti prevalence, as also demon-
strated elsewhere [47, 48]. Revising the current WHO
strategy for L. loa areas from MDA, to focus more on
ensuring effective vector control, through ITNs/LLINs,
integrating point-of-care test-and-treat options into
health systems and consolidating closer links with the
malaria control programme, may be a better use of the
limited resources available for LF elimination
programmes.
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